GlassScriptPhysician profile
Sang Kim
NPI 1023054202
$5,209.65
in general payments reported to CMS, 2019-2025
34 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,560 · 2020: $786 · 2021: $228 · 2022: $201 · 2023: $263 · 2024: $543 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $552.60 | 2019-2025 | Aveir, Jot Dx, Esprit |
| Amarin Pharma, INC. | $513.57 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $497.32 | 2019-2022 | |
| Boston Scientific Corporation | $472.87 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Janssen Pharmaceuticals, INC | $292.30 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.90 | 2019-2025 | Jardiance |
| Pfizer INC. | $282.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $243.79 | 2019-2025 | Farxiga |
| Arbor Pharmaceuticals, INC. | $215.31 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $195.26 | 2019-2025 | Camzyos |
| Gilead Sciences, INC. | $166.26 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $164.91 | 2019-2020 | |
| Amgen INC. | $164.11 | 2019-2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $151.02 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.21 | 2019-2023 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $146.39 | 2020-2025 | Extended Holter |
| Sanofi-Aventis U.S. LLC | $118.76 | 2019 | |
| Biotronik INC. | $68.66 | 2020-2021 | |
| Novo Nordisk INC | $66.33 | 2024-2025 | Ozempic |
| Edwards Lifesciences Corporation | $57.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.70 | 2019 | |
| Penumbra, INC. | $46.03 | 2024 | Indigo System |
| Medtronic, INC. | $38.87 | 2023 | Linq II |
| Allergan, INC. | $35.09 | 2019 | |
| Kestra Medical Technology Services, INC. | $34.68 | 2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $26.03 | 2023 | Inpefa |
| Medtronic Vascular, INC. | $25.01 | 2019 | |
| Portola Pharmaceuticals, LLC | $23.78 | 2019 | |
| Lundbeck LLC | $22.33 | 2020 | |
| Lantheus Medical Imaging, INC. | $22.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.34 | 2023 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $19.03 | 2025 | |
| Cardiva Medical, INC. | $18.30 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Glaxosmithkline, LLC. | $15.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sang Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.